Opinion|Videos|November 12, 2025
Defining Future Needs for Real-World Evidence in mCRC
Panelists discuss how future RWE should expand to include survival, quality of life, and safety data to improve third-line mCRC care.
Advertisement
Episodes in this series
Panelists identify gaps in current evidence and the need for more comprehensive real-world data to guide third-line therapy in metastatic colorectal cancer (mCRC).
They suggest future real-world evidence (RWE) should capture not only survival outcomes but also patient-reported quality of life, adherence, and broader safety signals.
Such data could enhance treatment personalization and support health system adoption of evidence-based third-line strategies.
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5